Beyond the Bone Health: A Narrative Review Unveiling the Role of Bisphosphonates in Reducing the Risk of Myocardial Infarction.

Bisphosphonates, a class of anti-osteoporotic drugs, are known to inhibit bone resorption and reduce fracture risk. This review evaluates the evidence for their use and also aims to assess their potential benefits, safety, and effectiveness in reducing the risk of myocardial infarction. Bisphosphonates, in addition to their conventional role in bone health, reduce the accumulation of calcium within vascular walls. Therefore, they are known to decrease the potential risk of myocardial infarction in patients with a higher likelihood of cardiovascular problems. However, they may exacerbate other cardiac issues and do not appear to reduce mortality rates. Bisphosphonates, when used as an anti-osteoporotic drug, generally have a favorable safety profile in patients with osteoporosis, regardless of treatment duration, age, sex, or underlying cardiovascular conditions. Nonetheless, strict adherence to bisphosphonate therapy over a longer duration may help reduce the risk of myocardial infarction.